Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MeziKD in Relapsed or Refractory Multiple Myeloma With Extramedullary Disease
NCT06627751Phase 2Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- May 2025
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 2 trial of mezigdomide in multiple myeloma (MM), sponsored by Roswell Park Comprehensive Cancer Center. Started May 2025; status: recruiting.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06627751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627751.